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LIST OF ABBREVIATIONS  
 
ADA   Adalimumab 
AE   Adverse event 
BMI   Body mass index 
CD   Crohn’s disease 
CI   Confidence interval 
CRP   C-Reactive Protein 
EIM   Extra-intestinal manifestation 
ELISA   Enzyme-linked immunosorbent assay 
FCAL   Faecal calprotectin 
GBP   Great British Pounds 
HBI   Harvey Bradshaw Index 
IBD   Inflammatory bowel disease 
IBD-U   Inflammatory bowel disease unclassified 
IQR   Interquartile Range 
n   Number 
PYF   Person years of follow-up 
NHS   National Health Service 
TNF   Tumor necrosis factor 




















Background and aims 
Multiple adalimumab (ADA) biosimilars are now approved for use in IBD; however, effectiveness 
and safety data remain scarce. We aimed to investigate long-term outcomes of the adalimumab 
(ADA) biosimilar SB5 in IBD patients following a switch from the ADA originator (SB5-switch 
cohort) or after start of SB5 (SB5-start cohort). 
Methods 
We performed an observational cohort study in a tertiary IBD referral centre. All IBD patients treated 
with Humira® underwent an elective switch to SB5. We identified all these patients in a biologic 
prescription database that prospectively registered all ADA start and stop dates including brand 
names. Data on IBD phenotype, CRP, drug persistence, ADA drug and antibody levels, and faecal 
calprotectin were collected. 
Results 
481 patients were treated with SB5, 256 in the SB5-switch cohort (median follow-up: 13.7 months 
[8.6-15.2]) and 225 in the SB5-start cohort (median follow-up: 8.3 months [4.2-12.8]). 70.8% of the 
SB5-switch cohort remained on SB5 beyond one year; 90/256 discontinued SB5, mainly due to 
adverse events (46/90) or secondary loss of response (37/90). In the SB5-start cohort, 81/225 
discontinued SB5 resulting in SB5-drug persistence of 60.3% beyond one year. No differences in 
clinical remission (p=0.53), CRP (p=0.80), faecal calprotectin (p=0.40) and ADA trough levels 
(p=0.55) were found between baseline, week 26 and week 52 following switch. Injection site pain was 
the most frequently reported adverse event. 
Conclusion 
Switching from ADA originator to SB5 appeared effective and safe in this study with over 12 months 
of follow-up.  
Keywords 





















Monoclonal antibodies directed against tumor necrosis factor (TNF), such as adalimumab (ADA) and 
infliximab (IFX), are widely used in the treatment of moderate to severe inflammatory bowel disease 
(IBD). They can successfully induce and maintain remission as well as reduce surgical rates and IBD-
related hospitalisations.
1, 2 However, anti-TNF therapy is costly and accounts for up to 73% of the 
annual IBD-related healthcare costs.
3, 4
 Indeed, it has been estimated that the United Kingdom 




Biosimilar agents represent a great potential in cost savings given their reduced pricing and their use 
may help improve patient access to anti-TNF therapy.
6
 In 2013, the first biosimilar for IFX (CT-P13) 
was licensed for use in IBD, whereas biosimilars for ADA have only been available since 2017. 
Although several studies have now demonstrated the safety and effectiveness of IFX biosimilars, data 
on ADA biosimilars are scarce. Currently, no randomised controlled trials comparing ADA 
biosimilars with the originator are available for IBD.
6, 7
 A small number of real-world studies have 
looked at outcomes of bio-naive patients as well as patients switching to biosimilar ADA from 
originator, however they are limited by size and long-term follow-up.
8, 9
 Furthermore, there are no 
data available looking at IBD patients who have undergone a double biosimilar ADA switch. 
In the Edinburgh IBD unit we previously implemented a managed switch program to guide the 
transition from the originator IFX to biosimilar CT-P13.
10
 In 2019, a similar process was adopted for 
patients switching to biosimilar SB5 from originator ADA. We aimed to investigate the effectiveness 
and safety of SB5 (Imraldi®) in (1) IBD patients who underwent a switch from the ADA originator 
(Humira®) to the biosimilar SB5, and in (2) IBD patients who commenced SB5 without previously 
being treated with the ADA originator. Moreover, we aimed to describe the prescribing trends of 






















We performed a retrospective observational cohort study in NHS Lothian (Scotland) to investigate the 
long-term effectiveness and safety of SB5. NHS Lothian provides all healthcare for a population of 
907,580 people in Edinburgh and the surrounding areas (estimate 2019).
11
 Four hospitals serve this 
area including the Western General Hospital (principal IBD unit), the Royal Infirmary of Edinburgh, 
St John’s Hospital and the Royal Hospital for Sick Children. More than 7,000 patients in NHS 
Lothian are diagnosed with IBD, referred to as the Lothian IBD cohort.
12
 
Since 1 February 2019, all adult (>18 years) IBD patients in NHS Lothian who were on maintenance 
therapy with the ADA originator underwent an elective switch to the biosimilar SB5 regardless of 
IBD phenotype, disease activity and ADA dosing. This switch took place after careful patient 
counselling, giving patients the opportunity to discuss this switch process further via a telephone 
consultation. Dosing and interval remained unchanged following the switch to SB5 unless clinical 
need dictated therapy adjustments. Adult patients who started ADA after 1 December 2018, directly 
commenced on the biosimilar SB5. All patients were reviewed regularly (approximately every 6 
months) in a virtual biologic clinic. At this time, clinical disease activity, laboratory parameters 
(including CRP), therapeutic drug monitoring and faecal calprotectin (FCAL) were collected by 
protocol if these data were not collected in the last 2 months. 
 
Patient identification 
Lloyds Pharmacy Clinical Homecare provides ADA for all NHS Lothian IBD patients since 2016. 
They prospectively register all ADA prescriptions including brand names, start dates and stop dates. 
Prescribed ADA brands included Humira®, Imraldi® (SB5) and Amgevita® (ABP 501), noting that 
ABP 501 was the first choice biosimilar in paediatric patients. A search in the Lloyds Pharmacy 
homecare prescription database was performed to identify all IBD patients in NHS Lothian who were 
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All patients with a confirmed IBD diagnosis and at least one dose of SB5 were eligible for inclusion. 
We included both patients who switched from the ADA originator to the biosimilar SB5 (SB5-switch 
cohort) and ADA-naïve patients who commenced SB5 (SB5-start cohort). Previous anti-TNF 
exposure was allowed. Patients who previously used ADA and discontinued ADA treatment before 
starting SB5 were included in the SB5-start cohort. We excluded patients with less than one month 
follow-up after starting SB5.  
 
Outcomes 
The primary outcome of this study was SB5 drug persistence in both the SB5-switch and SB5-start 
cohort. Secondary endpoints included biochemical, faecal biomarker and clinical remission, 
immunogenicity parameters (ADA drug and antibody levels), and safety parameters (adverse events).  
We assessed remission in the SB5-switch cohort as close to week 26 and week 52 (+ 10 weeks). 
Biochemical remission was defined as a CRP < 5 mg/l; biomarker remission was defined as a FCAL 
< 250 µg/g
13
; and clinical remission was efined as a Harvey Bradshaw Index (HBI) < 4 for Crohn’s 
disease patients or a partial Mayo index < 1 for ulcerative colitis patients.
14-17
  
Furthermore, we assessed ADA drug use over time in the Lothian IBD cohort. To this end, we 
reported the prevalent number of IBD cases on ADA per brand per year since 2010. 
 
Data collection 
Patient demographics and disease characteristics were extracted from electronic medical health 
records (TrakCare®). We collected the following baseline characteristics: sex, medical history, 
smoking history, body mass index (BMI), IBD type, age at IBD diagnosis, disease extent and 
phenotype according to the Montreal classification, previous IBD-related surgery, and both previous 
and ongoing exposure to IBD-related medical therapies. Start and stop dates of the different ADA 
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treatment discontinuation were recorded. Primary non-response was defined as lack of clinical or 
biochemical improvement after at least 8 weeks of induction therapy, requiring drug discontinuation. 
Secondary loss of response was defined as initial response to induction therapy but subsequent loss of 
response to maintenance therapy, requiring drug discontinuation.
18
 Furthermore, we collected data 
regarding the ADA dose and dose adjustments. Adverse events during follow-up were documented. 
Given the retrospective nature of this study, adverse events were not systematically recorded in the 
medical records. Therefore, we only documented adverse events that led to SB5 suspension or 
discontinuation, or hospitalisation. To assess treatment effectiveness, we extracted clinical scores and 
several biochemical parameters, including CRP, FCAL and ADA drug and antibody levels, at 
baseline (start SB5) and during follow-up. 
 
Adalimumab trough and antibody assay 
Until December 2017, ADA trough and antibody levels were processed at the Exeter Hospital 
Laboratories, United Kingdom, using the Immundiagnostik monitor enzyme-linked immunosorbent 
assay (ELISA) as per the manufacturer’s protocol. Trough levels and antibody levels were expressed 
in ug/mL and AU/mL, respectively. The assay detects drug levels ≥0.8 ug/mL and total antibodies to 
ADA ≥10 AU/ml. Drug assays were validated for both the ADA originator and for SB5.
19
 
Since January 2018, ADA drug monitoring has been delivered by the Queen Elizabeth University 
Hospital site, Glasgow, United Kingdom, using Immundiagnostik monitor ELISA as per the 
manufacturer’s protocol. The lower and upper limits are respectively <0.4 ug/ml and >12 ug/ml for 
trough level measurement, and <10 AU/ml and >200 AU/ml for ADA antibody level testing. 
Antibody testing is only performed when trough levels are below the therapeutic range (<5 ug/ml) or 
when ADA antibodies have previously been detectable.
20
  
Faecal calprotectin analyses  
FCAL was measured as part of routine clinical monitoring and as directed by patient symptoms. 
Patients received a FCAL collection kit with instructions and were asked to return their sample to the 
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forwarded the same day). They were advised to obtain a sample from the first bowel movement of the 
day and return their samples within 24 hours of collection. Upon arrival at the laboratories, samples 
were stored at –20°C. FCAL was measured using a standard ELISA technique (Calpro AS, Lysaker, 
Norway). Numerical values were generated between 20 and 2500 ug/g. All assays were performed in 
the Department of Clinical Biochemistry at the Western General Hospital, Edinburgh, United 
Kingdom. The same assay has been utilized since 2004. 
 
Statistics 
All analyses were performed with IBM SPSS statistical software package version 25 [Armonk, NY]. 
Descriptive statistics were used to describe baseline characteristics. Continuous variables are 
expressed as medians and interquartile range or mean and standard deviation, depending on 
distribution. Since the SB5-switch and SB5-start cohorts represent two different non-comparable 
cohorts (An IBD cohort which already started ADA therapy in the past versus a cohort with active 
IBD commencing SB5), it is of limited relevance to compare both groups. To this end, we have not 
compared descriptive statistics between both cohorts.  
Drug persistence was established with Kaplan Meier curves. Time-to-event was calculated from the 
start of SB5 treatment until SB5 discontinuation. Patients were censored at the end of follow-up, 
which was defined as last gastroenterology-related medical contact or patients’ death.  
Clinical, biochemical and faecal biomarker remission were analysed as categorical variables. Data 
were collected as close to baseline (within 26 weeks before SB5 commencement), week 26 (+ 10 
weeks) and week 52 (+ 10 weeks). We performed an intention-to-treat analysis with the last 
observation carried forward for patients who discontinued SB5. Comparison of parameters at the three 
different time points (baseline, week 26 and week 52) was performed via Friedman analysis.  
ADA trough levels and antibody levels were analysed as continues and categorical variables, 
respectively. We considered antibody levels of >10 AU/ml as detectable antibodies, whereas levels 
<10 AU/ml or absent measurements (due to adequate trough levels) were considered as indetectable 



















This work was considered a service evaluation/audit as all data were collected as part of routine 
clinical care. Therefore, no written consent or formal ethical approval was necessary as per 
departmental policy and Health Research Authority guidance. Caldicott guardian approval (NHS 
Lothian) was granted for anonymized data collection, analysis and submission for publication without 




481 patients, including 256 patients who switched from the ADA originator to SB5 and 225 patients 
who started on SB5 were included (Figure 1). The median duration of follow-up was 13.7 months 
(8.6-15.2) in the SB5-switch cohort and 8.3 months (4.2-12.8) in the SB5-start cohort, corresponding 
with 254 and 170 person years of follow-up (PYF), respectively. 88.1% (SB5-switch cohort) and 
36.7% (SB5-start cohort) of patients who continued ADA had over 12 months of follow-up after 
starting SB5. The baseline characteristics of both the SB5-switch and SB5-start cohort are displayed 
in Table 1 and Table 2.  
 
SB5-switch cohort 
Most patients in the SB5-switch cohort were diagnosed with CD (228/256, 89.1% versus 28/256, 
11.0% with UC/IBD-U). 52.7% were male (135/256) with a median IBD duration of 10 years (5.8-
16.2) before commencing SB5. The majority of patients had ileocolonic CD (46.9%) and 27.6% 
(63/256) had perianal disease activity. Patients were treated for a median of 32.5 months (16.4-55.9) 
with the originator prior to switching (minimum duration of treatment with the originator: 6 months). 
53.9% (138/256) patients were biologic naïve before use of ADA.  
At switch from the originator to SB5, 60.8% (155/256) received 40 mg ADA every other week and 
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(45/256, 17.6%) or methotrexate (11/256, 4.3%). 10.6% (27/256) patients underwent an SB5 dose 
intensification during treatment. 
 
SB5-start cohort 
The majority of patients included in the SB5-start cohort had CD (175/225, 77.8%). 50.2% (113/225) 
were male with a median IBD duration of 6.3 years (1.5-17.1) before starting SB5. Penetrating disease 
occurred in 30.6% (53/225) of the patients and 27.7% (48/207) had perianal disease. 68.6% (153/225) 
was biological-naive. 11/225 patients who started on SB5 previously used ADA. This was stopped 
median 27.3 (11.1-35.5) months before start of SB5 due to secondary loss of response (n = 3), 
pregnancy (n = 2), adverse events (n = 2), disease remission (n = 2), IBD-related surgery (n = 1) or 
loss of patient contact for drug delivery (n = 1). 
Almost all patients received a dose of 40 mg every other week (220/225, 97.8%). Two patients started 
on 40 mg weekly since they used ADA in the past. Combination therapy with a thiopurine or 
methotrexate was prescribed in 37/225 patients (16.5%). 21.3% (48/225) of patients required SB5 





In total, 90/256 (35.2%) patients discontinued SB5 treatment during a median follow-up time of 13.7 
months (8.6 – 15.2). Main reasons to stop therapy were adverse events (n = 46/90) and secondary loss 
of response (n = 37/90). 213/252 (84.6%) and 163/236 (70.8%) patients remained on SB5 at week 26 
and week 52, respectively (Figure 2). The majority of patients who stopped SB5 due to side effects 
switched to another ADA brand (see paragraph with safety outcomes), resulting in higher ADA drug 
persistence. As such, 228/251 (90.9%) and 190/232 (83.1%) patients remained on ADA at week 26 




















81/225 patients (36%) discontinued SB5 in 18.3 months (4.2 – 12.8) of follow-up, mainly due to 
primary non-response (n = 22/81), secondary loss of response (n = 26/81) and adverse events (n = 
24/81). At week 26 and 52, 137/181 (77.8%) and 65/134 (60.3%) patients remained on SB5 treatment, 
respectively (Figure 2). A minority of patients (7/225; 3.1%) who discontinued SB5 switched to 
another ADA brand resulting in overlapping ADA and SB5 drug persistence curves. 140/179 (80.1%) 





At baseline, 69.9% (123/176) of patients were in biochemical remission, 69.6% (94/135) were in 
faecal biomarker remission and 82.1% (170/207) were in clinical remission (Figure 3). Median CRP 
was 2 mg/L (1-6) and median FCAL was 95 ug/g (30-390). Proportions of patients in biochemical 
remission, faecal biomarker remission and clinical remission were similar at baseline, week 26 and 
week 52 following switch (Figure 3; p = 0.80, p = 0.40, p = 0.53, respectively). In addition, no 
differences were observed among m dian CRP and FCAL levels at different time points (median CRP 
week 26: 2 mg/L [1-6], median CRP week 52: 2 mg/L [1-8.3], p = 0.48; median FCAL week 26: 171 
ug/g [35-585], median FCAL week 52: 129 [37-574], p = 0.47). 
Immunogenicity 
SB5-switch cohort 
ADA trough levels and antibodies were measured within 18 months before switch in 207/256 patients. 
Median trough level was 10.1 ug/ml (7.3 – 12.6) with 10.1% (21/207) of patients found to have 
detectable antibodies to ADA (>10 AU/ml; Figure 3 and Supplementary Figure 1). 47.6% of these 
patients (10/21) discontinued SB5, whilst 38.1% (8/21) continued therapy and 14.3% (3/21) switched 
to the biosimilar ABP 501. Patients with detectable antibodies before switch had a significantly 
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At week 26 and week 52, SB5 was continued in 213 and 163 patients, respectively. 26/213 patients 
underwent dose adjustments before week 26 (16/26 dose intensification, 7/26 dose de-escalation, 3 
temporarily suspended), resulting in a median ADA trough level of 11.6 ug/ml (8.3 – 17.2; n = 65 
measurements available) at week 26. Before week 52, 31/163 patients underwent therapy adjustments 
(15/31 dose intensification, 11/31 dose de-escalation, 5 temporarily suspended) with subsequently 
trough levels of 7.8 ug/ml (5.4 – 11.3; n = 44 measurements available) at week 52. Allowing therapy 
adjustments dictated by clinical care, trough levels were not significantly different over time (baseline 
vs week 26 vs week 52: p = 0.55). 
27/256 patients (10.5%) had detectable antibodies following the switch to SB5. 8/27 patients had pre-
existing detectable ADA levels at baseline and 5/27 patients never underwent a drug assay prior to 
switch. Thus, 19 patients developed new detectable antibodies. These antibodies were detected after 
median 40 weeks (16-55). 17/19 patients received an immunosuppressant before switch and 4/19 were 
treated with azathioprine (n = 3) or methotrexate (n =1) during SB5 treatment.  
 
SB5- start cohort 
Therapeutic drug monitoring was performed 3 months after SB5 commencement as part of standard 
clinical care in the virtual IBD clinic. At this time point, ADA trough levels and antibodies were 
available in 153/225 patients. Median ADA trough level was 9.4 ug/ml (6.1-12.0) and 28/153 (18.3%) 
patients had detectable antibodies to ADA. Most patients who developed detectable antibodies were 
on ADA monotherapy (24/28 monotherapy, 4/28 combination therapy with azathioprine). 2/28 
patients who developed antibodies were previously treated with the ADA originator (treatment 
duration 6.6 and 8.4 years) and discontinued the originator 28 and 36 months before commencement 
of SB5.  
In a median follow-up duration of 8.3 months (4.2-12.8) 182/225 patients underwent therapeutic drug 
monitoring at some point. 40/182 patients (22.0%) developed newly detectable antibodies over time 




















Adverse events that required SB5 suspension or discontinuation, or hospitalisation were reported in 
51/256 patients in the SB5-switch cohort (Table 3). This results in an adverse event rate of 20.1 per 
100 PYF. 41 Adverse events were reported in 39/225 patients in the SB5-start cohort (Table 3), 
resulting in an adverse event rate of 24.1 per 100 PYF. 
 
SB5-switch cohort 
Pain at the injection site was the most frequently reported adverse event in the SB5-switch cohort (n = 
34; 13.4 per 100 PYF). 33 of these 34 patients switched either to another ADA biosimilar ABP 501 (n 
= 31) or back to the originator (n = 2). Three additional patients developed a skin rash after SB5 
administration of whom two patients switched back to the originator. Five patients developed an 
infection requiring (temporary) SB5 discontinuation.  
 
SB5-start cohort 
The most frequently reported adverse event in patients who started on SB5 were infections (n = 17; 
10.0 per 100 PYF). 7/17 infections (41.2%) required permanent treatment discontinuation, whereas 10 
infections required temporary suspension of SB5.  
Six patients in the SB5-start cohort reported pain at the injection site and all these patients switched to 
the biosimilar ABP 501. In addition, skin lesions were frequently reported (n = 8); 1/8 patients 
switched to ABP 501.  
 
Double biosimilar switch 
35 patients underwent a double biosimilar switch from the ADA originator to SB5 and subsequently 
to ABP 501. Most of these patients had CD (CD: 31/35, 88.6%; UC: 3/35, 8.6%; IBD-U 1/35, 2.9%). 
They were treated for median 30 months (18-50) with the originator. After median 28 weeks (15-43) 
patients were switched from SB5 to ABP 501 (n = 31) or back to the originator (n = 4). All patients 
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2). One patient continued to have pain at the injection site after a second biosimilar switch to ABP 
501 and switched back to the originator. None of the patients underwent dose adjustments of the 
second ADA brand or discontinued ADA in a median follow-up duration of 34 weeks (24 – 46). 
ADA trough levels before, after the initial switch, and after the second switch were available in 28, 
17, and 19 patients, respectively. In respective, median trough levels were 10.0 ug/ml (7.4 – 21.7), 
12.0 ug/ml (8.7 – 18.5) and 12.0 (7.9 – 12.0; Supplementary Figure 3). ADA trough levels were 
available at all three timepoints in six patients. A significant difference was found between trough 
levels at these time points (p < 0.01) with lower trough levels whilst treated with the originator. 
However, post-hoc comparisons between time points (including more patients) did not show any 
significant differences (data not shown). Moreover, it should be noted that 6/35 patients underwent 
SB5 dose intensification. 
Three patients had detectable ADA antibodies before switch to SB5. No detectable antibodies were 
found during follow measurements in these patients. Two patients developed new detectable 
antibodies during SB5 treatment. Follow-up drug assays were not available for these patients. None of 
the patients developed new detectable antibodies during ABP 501 treatment.  
 
Adalimumab use in the Lothian IBD cohort 
An increase in absolute ADA prescriptions was seen over time with on average 77 prescriptions in 
2010/2011 and 516 prescriptions in 2019/2020 (Figure 4). ADA was prescribed 6.7 times as much in 
2019/2020 compared to 2010/2011. This increase in ADA prescriptions is not exclusively caused by 
rising IBD prevalence, but also by earlier and more frequent use of ADA as this increase in 
prescriptions outpaces the increase in IBD prevalence seen in Lothian. IBD prevalence in Lothian rose 
by 4.3% per year between 2008 and 2018.
2, 12





















In our managed switch program, we actively switched IBD patients from the ADA originator to the 
biosimilar SB5. We showed in this large real-world cohort that this was safe, with acceptable drug 
persistence, no changes in clinical or biochemical activity over time and stable trough levels over 12 
months of follow-up. The most common adverse event was injection site pain; these patients were 
successfully moved on to ABP 501 providing the first data about a double biosimilar switch. 
Furthermore, our data showed that the biosimilar SB5 is efficient and safe in patients who 
commenced new treatment with SB5.  
Approval of the biosimilar SB5 is based on a phase III trial in rheumatoid arthritis patients that 
showed an efficacy comparable to the ADA originator in the induction of clinical remission.
21
 
Through extrapolation of indications, SB5 is approved for use in IBD patients. Our real-world IBD 
cohort provides effectiveness data for SB5 that shows comparability with the ADA originator. ADA 
drug persistence (which may serve as a proxy for real-world therapeutic benefit and safety
22
) after one 
year was 62.5% in our SB5-start cohort and 83.1% in our SB5-switch cohort. This is in line with drug 
persistence data from previous studies with the originator, reporting one-year ADA drug persistence 
between 45% and 74 % depending on previous biological use, disease type and sex.
22, 23
 In addition, 
one Italian study recently analyzed safety and effectiveness of SB5 in IBD patients. They reported 
that 66.7% of ADA-naive patients (n = 48) and 81.6% of patients who switched from the originator to 
SB5 (n = 98) remained on SB5 beyond one year.
9
 Moreover, similar proportions of clinical remission 
were found in this study one year after the switch to SB5 (74.5% vs 75.4% in our study).
9
 Another 




Further evidence that supports a comparable effectiveness of SB5 to the originator is based on the 
proportions of primary non-response and secondary loss of response in our study. According to the 




















 Secondary loss of response is reported in 24-46% of patients in the first year of 
treatment.
24, 28
 Compared to the literature, we found very reassuring but relatively low percentages of 
non-response (9.8% primary non-response, 11.6% secondary loss of response) in our SB5-start 
cohort. This is partly caused by lack of a uniform definition, in which some publications consider loss 
of response as the need for dose escalation whereas others designate loss or response after cessation of 
anti-TNF.
28
 Since we used the latter definition, relatively low loss of response percentages were 
expected. Furthermore, not all patients in our study have completed three month or one year follow-up 
yet, meaning that these patients are still at risk to develop loss of response. As such, 193/225 patients 
of the SB5-start cohort completed three month follow-up and only 65/225 patients had follow-up 
beyond one year. One previous study describing their SB5 experience in IBD reported primary loss of 
response in 1/48 patients (2.1%) after three months and secondary loss of response in 12.5% (6/48) 
and 27.1% (13/48) after respectively 6 and 12 months.
9
 
We demonstrated that trough levels were adequate and stable over time with ADA antibodies 
detectable in 10.5% in the SB5-switch cohort (including 3.1% with already detectable antibodies 
before switch) and 22.0% in the SB5-start cohort. This is in line with two previous IBD studies 
showing stable ADA trough levels following a switch from the ADA originator to SB5.
8, 9
 The 
PANTS study (n = 955) described in 28.5% of patients antibodies to ADA at week 54 following 
commencement of the ADA originator.
24
 Our immunogenicity percentage (22.0%) was slightly lower, 
which may be caused by differences in duration of follow-up (median 8.3 months in the SB5-start 
cohort in our study versus 54 weeks in the PANTS study). Furthermore, no differences were found 
between SB5 and the originator with respect to the pharmacokinetic and immunogenicity profile in 
non-IBD trials. As such, a phase I trial in healthy volunteers and a phase III trial in rheumatoid 
arthritis showed comparable ADA serum concentrations and antibodies.
21, 29
 
Injection site pain was the most frequently reported adverse event and occurred significantly more 
often in the patients who switched to SB5 (SB5-switch cohort 13.7%; SB5-start cohort 2.7%; p < 
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discontinuation were documented. In line with our findings, the SB5 switch study from the Italian 
group described injection site pain in 24.7% (88.9% occurred in the switching cohort).
9
 This may be 
related to the citrate buffer used for SB5, causing significantly more injection site pain compared to 
other buffers such as saline or histidine.
30, 31
 Two previous studies compared a new citrate-free 
formulation of the ADA originator (with a smaller injection volume and smaller needle) with the 
original citrate-containing ADA originator in IBD
32
 and rheumatological arthritis patients.
33
 They 
found that the citrate-free ADA formulation was associated with statistically significant less injection 
site pain.
32, 33
 In another study (only available in abstract form) 744 patients underwent a non-medical 
switch to a citrate-containing ADA biosimilar (all rheumatology and dermatology patients) or to a 
citrate-free ADA biosimilar (all gastroenterology patients). Injection site problems were more likely 
to be reported with the citrate-containing biosimilar.
34
 Most patients who developed injection site pain 
in our cohort switched to ABP 501, a citrate-free ADA biosimilar. Only 1/39 patients who switched to 
ABP 501 continued to have pain at the injection site and switched back to the originator. This 
supports the hypothesis that injection site pain is related to the citrate buffer. Finally, it should be 
noted that injection site reactions are also frequently reported (13% - 38%) with the ADA originator.
1, 
35
 The fact that injection site pain is mainly reported in the SB5-switch cohort, may indicate a role for 
the nocebo effect. No other unexpected toxicity signals were found in our study.  
The current ECCO position statement on the use of biosimilars advocates against a double biosimilar 
switch within 6 months from an immunological point of view and due to lack of evidence.
36
 Our study 
provided one of the first data regarding a double ADA biosimilar in IBD patients. None of the double 
switch patients in our study (n = 35) discontinued ADA after the second switch and trough levels were 
stable over time. Supportive data are found in a recent phase III trial with 465 plaque psoriasis 
patients assessing the impact of multiple ADA biosimilar switches on safety and efficacy. No 
differences were found between patients who did not switch and patients who underwent four 
switches (reverse switching between ADA originator and biosimilar GP2017).
37
 In line, a recent IBD 
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persistence compared to the single switch group with an overall drug persistence of 94.9% in the total 
study population.
38
 No changes were observed in clinical activity scores and IFX trough levels over 
time. Similarly, the number of received infliximab biosimilars did not impact immunogenicity in 
another study (n = 140).
39
 A Dutch study reported similar IFX drug persistence in patients who 
underwent a reverse switch to the IFX originator (n = 75) compared to patients who continued the IFX 
biosimilar (n = 683) with stable trough levels over time.
40
 These safety and effectiveness findings of a 
double biosimilar switch are confirmed in smaller studies.
41, 42
 This advocates the allowance of a 
double biosimilar switch. 
Our data are of major importance for socioeconomic society and our supportive evidence for 
biosimilar use may improve access to ADA, especially in countries where healthcare costs and 
policies may limit the appropriate prescription of it. In recent years, the number of ADA prescriptions 
has significantly increased as emphasized in our cohort.
2, 6
 In line, biological therapies are the main 
cost driver in IBD accounting for 73% of costs in CD and 48% in UC after the first year of diagnosis.
4
 
Indeed, Humira is one of world’s top selling drugs in the last decade.
43
 In addition, the Global 
Monoclonal Antibodies Market has a 7.4% compound annual growth rate since 2016 for monoclonal 
antibodies used for immune-mediated inflammatory diseases, and it is estimated that 60 million USD 
will be spent in 2021 for monoclonal antibodies.
6
 Biosimilars bear a great cost-saving potential and 
ADA costs were significantly reduced in NHS Lothian by the managed switch program.  
Our study has several strengths including the large sample size of the SB5 cohort (n = 481) and the 
long-term follow-up (> 13 months in the SB5-switch cohort). Furthermore, our study provides both 
data for patients who switched to SB5 and for patients who commenced SB5 as a new treatment 
strategy. The prospective registration of ADA start and stop dates, including brand names, 
significantly contributes to completeness of data. Moreover, the protocol driven collection of clinical 
disease activity, blood tests, therapeutic drug monitoring and FCAL in the virtual biologic clinic 
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Nevertheless, some limitations should be addressed. First, the study design did not include a control 
arm that continued the ADA originator, which impede the comparison of safety and effectiveness data 
between groups. Second, some follow-up data were lacking despite prospective data collection in the 
virtual biologic clinic. Third, different ADA drug and antibody assays were used since January 2018 
when the Scottish Biologic drug monitoring was relocated from Exeter to Glasgow. However, this 
took place one year before the first patients started on SB5 and almost all drug assays were performed 
in Glasgow limiting the impact of it.  Finally, the cohort was heterogenous in terms of disease 
activity, ADA dosing, and dose adjustments. Treatment changes could be made at the responsible 
clinicians’ discretion, which was not standardized. However, this reflects real-world practice, 
allowing direct translation of results into daily clinical practice.  
In conclusion, switching from the ADA originator to SB5 appeared effective and safe in this study 
with over 12 months of follow-up. The most common adverse event was injection site pain; these 
patients were successfully moved on to ABP 501 providing data about a double biosimilar switch, 




















IBD baseline characteristics of the SB5-switch cohort and SB5-start cohort. 
 
IBD, inflammatory bowel disease; TNF, tumor necrosis factor; n, number; IQR, interquartile range   
Variable SB5-switch cohort 
(n = 256) 
SB5-start 
cohort 






Male sex, n (%) 135 (52.7) 113 (50.2) 0 












28 / 16 
Body Mass Index (kg/m2), median (IQR) 25.2 (22.6 – 29.6) 26.9 (23.5 – 
30.5) 
44 / 31 
Age at IBD diagnosis (years), median (IQR) 26.8 (18.5 – 37.9) 29.0 (21.9 – 
40.4) 
0 / 3 
IBD duration until SB5 start (years), median (IQR) 10.0 (5.8 – 16.2) 6.3 (1.5 – 17.1) 0 / 3 
IBD duration until Adalimumab start (years), median 6.5 (2.5 – 12.4) 6.3 (1.5 – 17.1) 0 / 3 
Duration ADA originator until SB5 (years), median (IQR) 
Duration ADA originator until SB5 (months), median 
(IQR) 
2.7 (1.4 – 4.7) 
32.5 (16.4-55.9) 
- 0 
IBD type, n (%) 
- Crohn's disease 











Ulcerative colitis extent, n (%) 
- Proctitis (Montreal E1) 
- Left sided colitis (Montreal E2) 









5 / 5 
Crohn’s disease extent, n (%) 
- Ileal (Montreal L1) 
- Colonic (Montreal L2) 
- Ileocolonic (Montreal L3) 
- Upper gastrointestinal disease (Montreal L4) 













0 / 2 
Crohn’s disease phenotype, n (%) 
- Non-stricturing, non-penetrating (Montreal B1) 
- Stricturing (Montreal B2) 









0 / 2 
Previous IBD-related surgery, n (%) 87 (34.0) 64 (28.4) 0 
Previous IBD-related medical therapy, n (%) 
- Thiopurines 
- Methotrexate 






















3 / 2 
0 / 2 
0 / 2 
1 / 2 
0 / 1 
0 / 1 



















Details of adalimumab dosing and follow-up in the SB5-switch cohort and SB5-start cohort. 
 
Variable SB5-switch cohort 
(n = 256) 
SB5-start cohort 




start cohort, n) 
Adalimumab dose at switch to SB5, n (%) 
- 40 mg every other week 
- 40 mg weekly 
- 80 mg weekly 
- 40 mg every 3 weeks 













1 / 0 
Concomitant IBD therapy during SB5 treatment, n (%) 
- Systemic steroids 













1 / 1 
 
SB5 dose adjustments after switch, n (%) 
- No 
- Yes, dose intensification 
- Yes, dose de-escalation 











1 / 2 
SB5 treatment discontinuation, n (%) 90 (35.2) 81 (36.0) 0  
Adalimumab treatment discontinuation, n (%) 55 (21.5) 75 (33.3) 0 
Time to SB5 treatment discontinuation (months), median 
(IQR) 
7.1 (3.9 – 11.1) 5.2 (3.4-10.0) 0 
SB5 stop reasons, n (%) 
- Primary non-response 
- Secondary loss of response 
- Adverse events 
- Adverse events and active disease 
- Patient request 
- Long-term remission  
- Pregnancy 
- Peri-operative discontinuation of therapy 
- Active EIM, requiring new therapy 
























Duration of follow-up (months), median (IQR) 13.7 (8.6 – 15.2) 8.3 (4.2-12.8) 0 
 
 



















Overview of adverse events in the SB5-switch cohort and SB5-start cohort requiring suspension or 
discontinuation of SB5, or hospitalisation. 
Adverse event SB5-switch cohort (n = 256) 
 









(n, % of  total 
cohort) 














(n, % of total 
cohort) 





Total number of 
patients 
51 48 16 (29 – 47) 39 31 26 (6 – 50) 




34 (13.3) 29 (16 – 43) 6 (2.7) 6 (2.7) 12 (4 – 28) 
- Infection 5 (2.0) 3 (1.2) 17, 49, 61 15 
(6.7) 
10 (4.4) 60 (32 –  72) 
- Joint pain 2 (0.8) 2 (0.8) 17, 38 2 (0.9) 2 (0.9) 9, 30 
- Infection + joint 
pain 
0 (0) 0 (0) - 2 (0.9) 2 (0.9) 39, 45 
- Rash / skin lesions 3 (1.2) 3 (1.2) 1, 17, 33 8 (3.6) 6 (2.7) 6 (2 – 28) 
- Other 7 (2.7) 6 (2.3) 41 (13 – 64) 6 (2.7) 5 (2.2) 19 (12 – 40) 
 
 
* In case of < 3 reported adverse events, absolute week numbers of permanent treatment 
discontinuation are reported. 
 



















Patient inclusion flowchart  
* 11/225 patients previously used the adalimumab originator; however, last injection with the 
originator was discontinued median 27.3 (11.1-35.5) months before the start of SB5. 
$ Six patients with both IBD and a rheumatological condition were not identified in the homecare 
prescription database since adalimumab was prescribed by the rheumatologist. 
IBD, inflammatory bowel disease; n, number 
FIGURE 2 
Drug persistence of SB5 and ADA in both the SB5-switch (A) and SB5-start cohort (B). 
ADA, Adalimumab 
FIGURE 3 
Clinical, biochemical and immunogenicity outcomes at baseline, week 26 and week 52 following 
switch in the SB5-switch cohort 
(A): Proportion of patients in biochemical remission (CRP < 5mg/l), faecal biomarker remission 
(faecal calprotectin < 250 µg/g) and clinical remission (Crohn’s disease HBI < 4; ulcerative colitis < 
1)  
(B): Adalimumab trough levels 
FIGURE 4 
Prevalent number of IBD cases on ADA per brand per year. 
Of note, one patient who switched from the originator to SB5, to ABP 501 switched back to the 
originator (in luded in the originator – SB5 – ABP 501 group). Three patients who switched from 
originator to ABP 501, switched back to the originator (included in the originator – ABP 501 switch 
group). Four patients who switched from the originator to SB5 switched back to the originator 
(included in the originator – SB5 switch group). 
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